Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The objective of the study was to generate the data necessary to determine the gabapentin
exposure produced by 4 dose levels of GEn (600 mg, 1200 mg, 1800 mg, and 2400 mg) or placebo,
and the corresponding relief of symptoms in subjects with Restless Legs Syndrome (RLS).